PTC Therapeutics is valued at $5.83 billion, driven by rapid revenue growth from its lead product Sephience, which accounts for 63% of its product revenue and is expanding globally. The company also has ST-920, a late-stage gene therapy for Fabry Disease acquired from Sangamo, awaiting FDA approval that could significantly boost its valuation. Key risks include heavy reliance on these two products and sensitivity to FDA decisions and sustained revenue growth. Overall, PTC offers a compelling risk-reward profile for investors.
Several leading balance transfer credit cards now offer introductory 0% APR periods of up to 21 months on purchases and balance transfers, allowing cardholders to pay down debt without accruing interest. Cards like the Wells Fargo Reflect® and BankAm...
Carrying credit card debt at an average 22% APR can cost over $1,300 annually in interest. Using a balance transfer card with a 0% introductory APR for up to 21 months, like the Citi® Diamond Preferred® Card, allows payments to go directly to the pri...
BNB Chain will activate the Pasteur hard fork on its BNB Smart Chain mainnet at 02:30 UTC on August 25, 2026. This upgrade mandates node operators to install client version 1.7.7 and removes certain obsolete settings to enhance bridge validation, val...
XRP is trading around $1.49, up 2.15% in the last 24 hours, with spot XRP ETFs seeing $13.24 million in net inflows on August 21, marking the third consecutive day of gains. Total XRP ETF holdings are close to $1.2 billion, indicating sustained inves...
Solana began its first formal governance vote on August 22, 2026, allowing validators to decide on three key proposals by August 27. These include adopting a Solana Constitution to formalize governance, doubling the annual disinflation rate from 15% ...
